|
The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Monday. ---------- Main Market small-cap winners ---------- Solvonis Therapeutics PLC, up 14% at 0.22 pence, reports positive SVN-002 data Great Southern Copper PLC, up 7.7% at 2.8p ProCook Group PLC, up 6.9% at 38.5p BATM Advanced Communications Ltd, up 6.8% at 15.28p, agrees sale of non-core businesses Vp PLC, up 5.5% at 485.5p ---------- Main Market small-cap losers ---------- Technologies New Energy PLC, down 22% at 25p Sealand Capital Galaxy Ltd, down 9.1% at 0.23p DeFi Development Corp UK PLC, down 9.1% at 14p Synthomer PLC, down 9.2% at 104.1p, issues trading update Neo Energy Metals PLC, down 6.3% at 0.75p ---------- AIM winners ---------- Proteome Sciences PLC, up 31% at 1.98 pence, wins target engagement chemoproteomics contract Kazera Global PLC, up 24% at 1.18p, secures $10.5 million arbitration settlement Europa Oil & Gas (Holdings) PLC, up 19% at 1.6p, extends farm-out completion deadline Fletcher King PLC, up 15% at 57.5p Futura Medical PLC, up 12% at 0.61p ---------- AIM losers ---------- eEnergy Group PLC, down 36% at 3.28p, cuts full-year earnings outlooks Transense Technologies PLC, down 15% at 48p, lowers full-year earnings forecasts Proservice Building Services Marketplace PLC, down 12% at 2.75p Cellbxhealth PLC, down 11% at 1.55p, revenue falls, pretax loss widens Lexington Gold Ltd, down 9.2% at 2.95p, reports final results, loss narrows ---------- Small-cap and AIM movers in focus: ---------- Solvonis Therapeutics PLC, up 14% at 0.22 pence, 12-month range 0.18p-0.39p. Reports positive pharmacokinetic data from the preclinical bridging study for its SVN-002 development programme. SVN-002 is its proprietary esketamine oral thin-film in development for moderate-to-severe alcohol use disorder. Solvonis says that at the same nominal dose level, combined sublingual-buccal administration of SVN-002 produced rapid systemic exposure to parent esketamine. Exposure levels for parent esketamine and the key measured metabolites, noresketamine and hydroxynoresketamine, were within the range observed for the intranasal esketamine comparator arm. This provides important translational support for the planned scientific bridge, it says. Company intends to seek further FDA feedback on the scope and scale of the remaining nonclinical toxicology work required for the initial investigational new drug submission. ---------- BATM Advanced Communications Ltd, up 6.8% at 15.28 pence, 12-month range 12.55p-19.75p. Enters a share purchase & loan assignment agreement with Haim Dor for the proposed sale of three of its remaining four non-core activities, which consist of seven corporate entities, including Sunstring Ltd, for $13.3 million in cash. Sunstring enters a secondary share purchase agreement, also with Dor, to sell 96.8 million BATM shares at 18.15p each for £17.6 million or around $23.3 million in cash. Cash consideration totals approximately $36.6 million. The businesses and shares will be sold to either Dor or an entity he controls. ---------- Proteome Sciences PLC, up 31% at 1.98 pence, 12-month range 1.28p-3.6p. Secures a ‘further significant clinical contract connected to its target engagement/chemoproteomics platform.’ Expects the contract to be a precursor to a new clinical trial programme, which it plans to start later this year. ---------- eEnergy Group PLC, down 36% at 3.3 pence, 12-month range 3.28p-6.45p. Cuts full-year revenue outlook to around £32.0 million from £38.0 million, and the adjusted earnings before interest, tax, depreciation and amortisation outlook to £1.7 million from £4.5 million. For financial 2025, eEnergy reported revenue of £19.0 million and adjusted Ebitda of £2.2 million. Also forecasts first-half revenue of around £22.0 million, up on-year from £10.1 million, and adjusted Ebitda of around £1.2 million, up from around £500,000. Chair Andrew Lawley notes that Interim Chief Executive John Cahan has ‘commenced a restructuring and cost saving exercise to simplify the reporting structure and right size the cost base,’ and says that following his appointment, ‘we have conducted a detailed review of the pipeline of potential sales opportunities. Consequently, the board now believes that investment grade opportunities equivalent to £66m more fairly reflect the level of live opportunities that the business could potentially convert into revenue in the short to medium term.’ ---------- Transense Technologies PLC, down 15% at 48 pence, 12-month range 48p-160p. Announces a ‘modest reduction’ to its forecasts for the year ending June 30. Now expects revenue of at least £4.6 million, adjusted Ebitda of at least £500,000, and ‘approximately break-even’ adjusted pretax profit. Cites lower-than-expected sales from global tyre manufacturers within Translogik, saying it expects demand to recover in financial 2027. Also expects Bridgestone iTrack royalty income of at least £2.0 million, and for financial 2027 to show ‘further modest growth’. Says it remains confident in its medium-term growth opportunities across both business segments. ---------- Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
